GLP-1 Medication or Bariatric Surgery? Why Surgery Need Not Be Last Dr. Ravi Rao November 18, 2026
favicon
DR. RAVI RAO

Weight Loss Surgeon

GLP-1 medication or bariatric surgery

GLP-1 Medication or Bariatric Surgery? Why Surgery Need Not Be Last

Do you have to fail GLP-1 medication before considering bariatric surgery?

For many years, obesity treatment has been described as a sequence: lifestyle changes first, medication next, and surgery only after everything else has failed.

That approach may not suit every patient.

GLP-1–based medications have expanded the options available for obesity management. At the same time, metabolic and bariatric surgery remains an established, evidence-based treatment for selected people with obesity.

These treatments are not necessarily competitors. Starting a GLP-1 medication does not mean a person must first “fail” it or try every other medication before bariatric surgery can be considered.

What did the latest Cleveland Clinic study examine?

A 2026 study published in eClinicalMedicine analysed electronic health records from 20,486 Cleveland Clinic patients who had initially received injectable semaglutide or tirzepatide for at least three months.

Using a target-trial emulation approach, researchers compared five treatment pathways over two years:

  • Continuing the original GLP-1 medication
  • Switching between GLP-1–based medications
  • Moving to another obesity medication
  • Undergoing metabolic or bariatric surgery
  • Stopping obesity treatment without another medication or surgical treatment.

What were the weight-loss outcomes?

At two years, the study reported the following average weight change from the initial medication fill:

Treatment pathwayAverage body-weight reduction at two years
Metabolic or bariatric surgery28.2%
Switching between GLP-1–based medications16.0%
Continuing the original medication10.9%
Switching to another obesity medication8.2%
Discontinuing treatment without another obesity treatment4.0%

The researchers also reported improvements in HbA1c among people with type 2 diabetes and systolic blood pressure among people with hypertension. In general, outcomes were better when people continued an effective treatment than when they stopped all obesity treatment.

What the study ‘does’ and ‘does not’ show

This was an observational study, not a randomised clinical trial. The researchers used statistical methods to account for measurable differences between groups, but treatment selection and unmeasured factors may still have influenced the results.

The findings do not mean that:

  • Surgery will produce a particular amount of weight loss for every person
  • Bariatric surgery should always be the first treatment
  • Continuing GLP-1–based medications represent the maximum possible benefit of these medicines
  • Someone who has not lost enough weight on medication has “failed” treatment

What the study does reinforce is that long-term outcomes depend on the treatment pathway. For some people, surgery may be an appropriate next step earlier in their obesity-care journey, not only after multiple medications have been tried.

Why surgery may be discussed earlier

The 2022 ASMBS/IFSO international guidelines recommend metabolic and bariatric surgery for people with a BMI of 35 or above, regardless of associated metabolic disease, and support considering surgery at a BMI of 30–34.9 in selected patients, particularly those with metabolic disease.

The decision to consider metabolic or bariatric surgery should be based on a person’s overall clinical situation, not simply on whether they have tried and stopped a particular medication.

A specialist assessment may consider:

  • The severity of obesity
  • Type 2 diabetes, high blood pressure, sleep apnoea, joint disease and other obesity-related conditions
  • Previous response to medication
  • Medication side effects, tolerability, cost and access
  • Expected durability of weight loss
  • Nutritional, psychological, and surgical considerations
  • The person’s goals, preferences, and readiness for treatment

An early surgical consultation does not commit someone to an operation. It provides an opportunity to understand the potential benefits, risks, alternatives, and long-term follow-up involved.

Can medication and surgery work together?

Yes.
GLP-1 medication may be used before surgery in selected patients, or after surgery when further weight loss is needed or weight begins to return. Conversely, someone who has already started a GLP-1 medication may still be an appropriate candidate for metabolic or bariatric surgery without first exhausting every available medication.

The most effective pathway may involve medication, surgery, nutritional support, behavioural care, or a combination of this over time. Ongoing follow-up remains important whatever treatment is chosen.

What this means for patients in Perth

The important question is not, “Which treatment should everyone try first?”

It is, “Which treatment is most appropriate for this person, at this stage of their obesity and metabolic health?”

At Perth Surgical & Bariatrics, we consider medical and surgical options as part of a broader, long-term obesity and metabolic care plan. This includes nutritional assessment, body-composition assessment where appropriate, and structured follow-up.

If you are using a GLP-1 medication, considering bariatric surgery, or unsure about your next step, a specialist assessment can help you understand the options and make an informed decision.

References
  1. Gasoyan H, et al. Comparative effectiveness of obesity treatments after initial therapy with semaglutide or tirzepatide: a target trial emulation using data from Cleveland Clinic electronic health records. eClinicalMedicine. 2026. doi:10.1016/j.eclinm.2026.104321.
  2. Cleveland Clinic. Study Identifies Best Treatment Strategies for Weight Loss After Stopping GLP-1 Drugs. 14 November 2026.
  3. Eisenberg D, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surgery for Obesity and Related Diseases. 2022;18(12):1345–1356. https://doi.org/10.1016/j.soard.2022.08.013

Related

Write a comment
Your email address will not be published. Required fields are marked *